Sana Biotechnology develops engineered cells aimed at treating and potentially curing various diseases. Their approach focuses on addressing the root causes of diseases by repairing genes within cells or replacing damaged cells. This method allows for the creation of new types of medicines that can enhance patient outcomes. Sana's main clients include healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The company invests heavily in research and development to discover and create new treatments, which they monetize through licensing agreements, partnerships, and direct sales. Unlike many competitors, Sana's focus on cellular and genetic medicine positions them uniquely in the biotechnology sector. Their goal is to improve patient care by providing effective treatments for a wide range of diseases, from genetic disorders to chronic conditions.

CPP Investments

Alaska Permanent Fund

Bezos Expeditions

PSP Investments

F-Prime

Altitude Life Science Ventures

Flagship Pioneering

ARCH Venture Partners

Baillie Gifford

Omega Funds

Biotechnology

Healthcare

Sana Biotechnology

Sana Biotechnology is expanding its team in Cambridge, MA with roles such as Principal Research Associate, Histology and Imaging Core Lab.

9 Companies Hiring in the Genetown Hotbed

The Seattle-based biotech expects to close the offering Monday.

Sana Biotechnology raising $165M through public offering

Sana Biotechnology to open a facility in Bothell to create and deliver engineered cells as medicines for patients.

Sana Biotechnology to open a facility in Bothell to create and deliver engineered cells as medicines for patients

In a recent development from Sana Biotechnology (NASDAQ:SANA), the company announced the resignation of Dr. Douglas Williams from his role as Executive Vice President and President of Research and Development.

Sana Biotechnology EVP Williams resigns from R&D post

SEATTLE, Jan. 08, 2025  (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Wednesday, January 15, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer

Sana Biotechnology To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

Ms. Tousignant joins Viridian most recently from Sana Biotechnology where she was Senior Vice President of Legal and led the legal team responsible for research and development, regulatory, quality, intellectual property, business development, corporate communications and investor relations, and litigation.

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025SEATTLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus (SLE), which includes extrarenal lupus and lupus nephritis. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.SC291, a hypoimmune (HIP)-modified CD19-directed allogeneic CAR T therapy, is being evaluated in Sana’s GLEAM trial in patients with B-cell mediated autoimmune diseases including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Sana is enrolling patients in this study and expects to share initial data in 2025.“We are pleased to receive Fast Track designation from the FDA for SC291, which highlights the need for new treatment options for patients with relapsed/refractory SLE,” said Dhaval Patel, M.D., Ph.D., Chief Scientific Officer of Sana

Sana Biotechnology Announces Fast Track Designation For Sc291 In Relapsed/Refractory Systemic Lupus Erythematosus

Sana Biotechnology has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $189,750,000.00 in New Equity Investment. Sana Biotechnology has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $189,750,000.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, Sana Biotechnology is raising $189,750,000.00 in new funding. About Sana Biotechnology: Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL

Sana Biotechnology Has Filed A Notice Of A Private Investment In Public Equity (Pipe) Offering Of Securities To Raise $189,750,000.00 In New Equity Investment.

Sana Biotechnology appoints accomplished drug developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.

Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

The field of stem cell therapy has gained traction over recent years, with companies transitioning from experimental stages to delivering practical treatments. Stem cells, with their unique ability to differentiate into various cell types, hold great potential in regenerative medicine.One of the most notable advancements in stem cell therapy is its application in treating neurodegenerative diseases such as Parkinson’s disease. Companies like BlueRock Therapeutics have pioneered the development of dopamine-producing neural cells derived from stem cells potentially altering the disease course​. Stem cell therapy has also shown potential in repairing damaged heart tissue or in cancer treatment research.In this article, we delve into stem-cell-oriented biotech companies to know about.Table of contentsAspen NeuroscienceAspen Neuroscience was founded in 2018, and is headquartered in San Diego. It is a clinical-stage company focused on developing personalized stem cell therapies to treat neurodegenerative diseases, with an initial emphasis on Parkinson’s disease.Aspen Neuroscience’s lead candidate, ANPD001, is an autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy aimed at treating Parkinson’s disease. This therapy is designed to replace the lost dopamine neurons that are characteristic of the disease, potentially reversing its effects.Aspen’s technology lies in the use of autologous iPSCs

Stem Cell Therapy’S Avant-Garde: Eight Companies Leading The Way

Develops engineered cell therapies for diseases

Sana Biotechnology

Develops engineered cell therapies for diseases

Sana Biotechnology

Develops engineered cell therapies for diseases

About

Simplify's Take

What believers are saying

What critics are saying

What makes Sana Biotechnology unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Sana Biotechnology is Hiring for 0 Jobs on Simplify!